One could try to reverse engineer their power calculations

New Post Public Reply Private Reply Replies (0) Message Board
kabonk havasu78 #72190
591
One could try to reverse engineer their power calculations and assumptions on the study, using a power calculator like here:

https://www2.ccrb.cuhk.edu.hk/stat/proportion/Casagrande.htm

Assuming 80% power used to estimate sample size, with one sided test (H0: P1=P2 vs. Ha: treatment with LL lowers mortality from no treatment / placebo; i.e. P2<P1), the study sample size is approximated by assuming P1=mortality with placebo at 30%, and P2=mortality with LL at 18%. (Gives N=378 sample size, close to 390). So, these might be close to the numbers estimated at trial start to get our sample size and trial powered properly.

When discussing stats, people haven't talked much about confidence intervals or the margin of error in estimating mortality rates in each group, but these are critical when calculating the difference in proportions (absolute difference in mortality in our trial), to prove that it does not include 0. i.e. we want our reduction in risk of death to be less 0%; so a 12% absolute reduction from 0.3 to 0.18 might have a 95%CI from -16% to -8%, which would be good. However if it's only from 0.23 to 0.2 difference in mortality with LL, that -3% might have a 95% CI from -8% to +2%, which is not significant (it could be 8% drop, but it could also be a 2% increase in risk from LL).

From this number, we can also get the number needed to treat to save one life. It is just 1/(P1-P2). If the difference is 12.5%, then we would need to treat 8 people to save one life. They reported this number recently for the UK IL-6 trial. Mortality in their controls was 35.8%; Tocilizumab had 28% and Sarilumab 22.2% death rate. Combined, the reduction was from 35.8% to 27.2%, or a relative reduction of 24%, and absolute of ~8.6%. The number needed to treat to save a life was thus around 12 patients.

https://www.dummies.com/education/math/statis...oportions/

A similar concept for comparing differnce in proportions is the risk ratio or related odds ratio, to prove that it does not include 1.0. i.e. we want our relative risk of death to be less than 1 when using LL, so .18/.30 is 0.6 (or a 40% relative reduction in mortality). The confidence interval of the risk ratio that will tell us if this is significant or not. If reduction is 0.6, with 95%CI from 0.3 to 0.9, then that would be great. If the reduction / RR is 0.8, with 95% CI from 0.3 to 1.3, then that would not be significant.

https://www.cureus.com/articles/39455-whats-t...ard-ratios

Stats are interesting, but I forget everything I may have learned and I'm sure I've mis-stated something above.



CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Tesla Stock Faces Market Challenges Amid California Proposals

Updated Category News Views 176

The Dynamics Surrounding Tesla Stock Tesla Inc (NASDAQ: TSLA) has been experiencing fluctuations in its stock value, closing lower recently. The latest reports suggest that Tesla vehicles may not be eligible for rebates due to new consumer rebate proposals in California. Understanding the Current Situation A recent report from Bloomberg highlighted new developments from...

Continue Reading
Acceleware Ltd. Expands Private Placement Financing Timeline

Updated Category News Views 173

Acceleware Ltd.'s Private Placement Financing Update Acceleware Ltd., a prominent innovator in radio frequency (RF) technology based in Calgary, has announced an extension regarding its ongoing private placement financing. This extension reflects the company's dedication to advancing process heat solutions applicable in crucial mineral processing, carbon capture...

Continue Reading
Lake Victoria Gold: Strategic Advancements in Gold Production

Updated Category News Views 162

Promising Gold Opportunities Gold mining is experiencing a resurgence, with miners like Lake Victoria Gold Ltd. (NASDAQ: LVGLF) at the forefront of significant advancements. As we witness a robust moment in the gold market, the anticipation for growth is palpable among investors. Analysts are optimistic about the performance of gold equities, noting that many remain...

Continue Reading
Pathward Financial Announces Upcoming Q1 2025 Earnings Call

Updated Category News Views 120

Pathward Financial to Announce Earnings for First Quarter 2025 Pathward Financial, Inc. has made an important announcement regarding its upcoming financial results for the first quarter of fiscal year 2025. The release is set for Tuesday, after the market closes, and the company is eager to share insights from these results. Conference Call Scheduled A conference call and...

Continue Reading
Collaboration Insights: Cardano and Solana Aim for Unity

Updated Category News Views 140

Cardano and Solana Forge New Relations Cardano (CRYPTO: ADA) founder Charles Hoskinson and Solana (CRYPTO: SOL) co-founder Anatoly Yakovenko are initiating a partnership aimed at linking their respective blockchains. This move signifies a major shift from the previously competitive stance to one of collaboration. Starting a New Chapter Yakovenko made a significant...

Continue Reading